Shannon L. Devers - 03 Sep 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP, Chief Human Resources Ofc
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers
Issuer symbol: IONS
Transactions as of: 03 Sep 2025
Net transactions value: -$78,736
Form type: 4
Filing time: 04 Sep 2025, 20:36:34 UTC
Previous filing: 17 Jan 2025
Next filing: 16 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Devers Shannon L.	EVP, Chief Human Resources Ofc	2855 GAZELLE COURT, CARLSBAD	By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers	04 Sep 2025	0002037721

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IONS	Common Stock	Options Exercise	$83,954	+2,234	+14%	$37.58	18,171	03 Sep 2025	Direct
transaction	IONS	Common Stock	Sale	$192,943	-3,162	-17%	$61.02	15,009	03 Sep 2025	Direct	F1, F2
transaction	IONS	Common Stock	Options Exercise	$30,253	+928	+6.2%	$32.60	15,937	03 Sep 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IONS	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-928	-6.5%	$0.000000	13,440	03 Sep 2025	Common Stock	928	$32.60	Direct
transaction	IONS	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-2,234	-15%	$0.000000	13,083	03 Sep 2025	Common Stock	2,234	$37.58	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.0075 to $61.045 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Content

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.0075 to $61.045 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.